The clinical value of local consolidative therapy for oligo-residual disease in PD-1/PD-L1 inhibitors-treated non-small cell lung cancer

作者：Yuqi Su, Pan Luo, Ling Ni, Jianbin Hu, Jie Weng, Erdong Shen, Qiang Zhou, Tao Chen, Jiwen Xiao, Xiao Jia, Wangti Xie, Rong Shan, Xiang Yao, Fang Wen · 发表于：Frontiers in Immunology · 年份：2024 · DOI：10.3389/fimmu.2024.1525236 · 被引用次数：6 · 研究领域：Cancer Immunotherapy and Biomarkers、Lung Cancer Diagnosis and Treatment、Radiomics and Machine Learning in Medical Imaging

Background: Few real-world studies exist regarding the clinical value of local consolidative therapy (LCT) for oligo-residual disease (ORD) in NSCLC patients treated with immune checkpoint inhibitors. Therefore, we retrospectively evaluated whether LCT could improve the prognosis of NSCL patients with ORD after effective first-line PD-1/PD-L1 inhibitors treatment. Methods: A total of 132 patients with metastatic NSCLC who had received first-line PD-1/PD-L1inhibitors-based systemic treatment and developed ORD (defined as residual tumors limited to three organs and five lesions) were included. The LCT group consisted of 41 patients received LCTs for oligo-residual lesions before treatment failure, and the remaining 91 patients, who did not receive local therapies, constituted the non-LCT group. The progression-free survival (PFS) and overall survival (OS) of the two groups were analyzed. Results: With a median follow-up of 12.0 months, 86 patients developed progressive disease and 42 patients died. Compared with the non-LCT group, LCT group exhibited significant longer progression-free survival (PFS) (median 11.0 vs. 7.0 months, P=0.017) and overall survival (OS) (median 26.0 vs. 17.0 months, P=0.003). Multivariable analysis demonstrated that LCT was an independent predictor of prolonged PFS (HR=0.606, 95% CI=0.370-0.964, P=0.035) and OS (HR=0.467, 95% CI=0.229-0.949, P=0.035). Subgroup analysis revealed that the dominant population considerably benefited from LCT in terms of P...